Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 6/2013

01-07-2013 | Brief Report

HIV-Negative and HIV-Positive Gay Men’s Attitudes to Medicines, HIV Treatments and Antiretroviral-based Prevention

Authors: Martin Holt, Dean Murphy, Denton Callander, Jeanne Ellard, Marsha Rosengarten, Susan Kippax, John de Wit

Published in: AIDS and Behavior | Issue 6/2013

Login to get access

Abstract

We assessed attitudes to medicines, HIV treatments and antiretroviral-based prevention in a national, online survey of 1,041 Australian gay men (88.3 % HIV-negative and 11.7 % HIV-positive). Multivariate analysis of variance was used to identify the effect of HIV status on attitudes. HIV-negative men disagreed with the idea that HIV drugs should be restricted to HIV-positive people. HIV-positive men agreed and HIV-negative men disagreed that taking HIV treatments was straightforward and HIV-negative men were more sceptical about whether HIV treatment or an undetectable viral load prevented HIV transmission. HIV-negative and HIV-positive men had similar attitudes to pre-exposure prophylaxis but divergent views about ‘treatment as prevention’.
Literature
1.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCrossRef
2.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.PubMedCrossRef
3.
4.
Editorial. HIV treatment as prevention—it works. Lancet. 2011;377(9779):1719.
5.
Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301(22):2380–2.PubMedCrossRef
6.
Imrie J, Elford J, Kippax S, Hart GJ. Biomedical HIV prevention and social science. Lancet. 2007;370(9581):10–1.PubMedCrossRef
7.
Editorial. Treatment as prevention for HIV. Lancet Infect Dis. 2011;11(9):651.
8.
van de Laar MJ, Pharris A. Treatment as prevention: will it work? Euro Surveill. 2011;16(48):2–4.
9.
Holt M, Murphy DA, Callander D, Ellard J, Rosengarten M, Kippax SC, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012;88:258–63.PubMedCrossRef
10.
Van de Ven P, Crawford J, Kippax S, Knox S, Prestage G. A scale of optimism–scepticism in the context of HIV treatments. AIDS Care. 2000;12(2):171–6.PubMedCrossRef
11.
Holt M, Mao L, Prestage G, Zablotska I, De Wit J. Gay Community Periodic Surveys: National Report 2010. Sydney: National Centre in HIV Social Research, The University of New South Wales; 2011.
12.
Australasian Society for HIV Medicine. HHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (March 28, 2012) with Australian commentary. Sydney: Australasian Society for HIV Medicine; 2012.
Metadata
Title
HIV-Negative and HIV-Positive Gay Men’s Attitudes to Medicines, HIV Treatments and Antiretroviral-based Prevention
Authors
Martin Holt
Dean Murphy
Denton Callander
Jeanne Ellard
Marsha Rosengarten
Susan Kippax
John de Wit
Publication date
01-07-2013
Publisher
Springer US
Published in
AIDS and Behavior / Issue 6/2013
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-012-0313-z

Other articles of this Issue 6/2013

AIDS and Behavior 6/2013 Go to the issue

Original Paper

Masivukeni: Development of a Multimedia Based Antiretroviral Therapy Adherence Intervention for Counselors and Patients in South Africa

Original Research

Acceptability and Uptake of Neonatal Male Circumcision in Lusaka, Zambia

Original Paper

Peer-Education Intervention to Reduce Injection Risk Behaviors Benefits High-Risk Young Injection Drug Users: A Latent Transition Analysis of the CIDUS 3/DUIT Study

Original Paper

Circumcision Status and Time to First Sex Among Never-Married Young Men in Malawi: Evidence from the Demographic and Health Survey

Original Paper

Color-Coded Audio Computer-Assisted Self-Interviews (C-ACASI) for Poorly Educated Men and Women in a Semi-rural Area of South India: “Good, Scary and Thrilling”

Original Paper

Enhancing Acceptability and Use of Sexual Barrier Products Among HIV Concordant and Discordant Couples
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits